Modulation of multidrug resistance (MDR) in hematological malignancies - PubMed (original) (raw)
Affiliations
- PMID: 10676553
Review
Modulation of multidrug resistance (MDR) in hematological malignancies
A Covelli. Ann Oncol. 1999.
Abstract
The term multidrug resistance (MDR) describes the observation that tumour cell lines can become cross-resistant to several structurally unrelated chemotherapeutic agents after exposure to a single cytotoxic drug. In hematological malignancies, MDR is most often associated with overexpression of P-gp, a 170-kd transmembrane glycoprotein encoded by the human MDRI gene. Indeed, P-gp expression has been correlated with drug sensitivity and clinical outcome in several studies in acute myelogenous leukemia (AML), multiple myeloma (MM), and malignant lymphomas (NHL). A large number of compounds 'off the shelf' have been investigated for their ability to reverse the P-gp mediated MDR. However, most of these agents produced severe toxic effects at doses required to effectively block P-gp function, and modulation of P-gp in normal tissues can affect the pharmacokinetics and, thus, the toxicity of the associated chemotherapeutic agents. Phase I/IIa trials with third generation MDR modulators, such as valspodar, show that these new agents can be safely administered in combination with different chemotherapy regiments after dose adjustments of cytotoxic drugs that a P-gp substrates. Moreover, MDR reversal by valspodar has been demonstrated in the patients with AML, multiple myeloma, and non-Hodgkin's lymphoma. The definition of the clinical benefits of using MDR modulators in haematological malignancies and their full extent awaits the conclusion of the ongoing randomized phase III trials with valspondar in either newly diagnosed or resistant relapsed AML patients, and in multiple myeloma patients who have failed front-line treatment.
Similar articles
- Multidrug resistance in haematological malignancies.
Sonneveld P. Sonneveld P. J Intern Med. 2000 May;247(5):521-34. J Intern Med. 2000. PMID: 10809991 Review. - Drug resistance in multiple myeloma.
Sonneveld P, Lokhorst HM, Vossebeld P. Sonneveld P, et al. Semin Hematol. 1997 Oct;34(4 Suppl 5):34-9. Semin Hematol. 1997. PMID: 9408959 Review. - Multidrug resistance (MDR) genes in haematological malignancies.
Nooter K, Sonneveld P. Nooter K, et al. Cytotechnology. 1993;12(1-3):213-30. doi: 10.1007/BF00744665. Cytotechnology. 1993. PMID: 7765326 Review. - Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Sikic BI, et al. Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. doi: 10.1007/s002800051055. Cancer Chemother Pharmacol. 1997. PMID: 9272128 Review. - Biology and modulation of multidrug resistance (MDR) in hematological malignancies.
Hirose M. Hirose M. Int J Hematol. 2002 Aug;76 Suppl 2:206-11. doi: 10.1007/BF03165119. Int J Hematol. 2002. PMID: 12430927
Cited by
- Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method.
Danışman Kalındemirtaş F, Birman H, Candöken E, Bilgiş Gazioğlu S, Melikoğlu G, Kuruca S. Danışman Kalındemirtaş F, et al. Balkan Med J. 2019 Feb 28;36(2):96-105. doi: 10.4274/balkanmedj.galenos.2018.2017.1244. Epub 2018 Nov 5. Balkan Med J. 2019. PMID: 30396879 Free PMC article. - Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC, Lin SF. Yang WC, et al. Biomed Res Int. 2015;2015:341430. doi: 10.1155/2015/341430. Epub 2015 Nov 16. Biomed Res Int. 2015. PMID: 26649299 Free PMC article. Review. - Reversal of multidrug resistance by 5,5'-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX.
Wang TX, Shi XY, Cong Y, Wang SG, Wang YY, Zhang ZQ. Wang TX, et al. Indian J Pharmacol. 2013 Nov-Dec;45(6):597-602. doi: 10.4103/0253-7613.121371. Indian J Pharmacol. 2013. PMID: 24347768 Free PMC article. - Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC. Hideshima T, et al. Blood. 2006 May 15;107(10):4053-62. doi: 10.1182/blood-2005-08-3434. Epub 2006 Jan 17. Blood. 2006. PMID: 16418332 Free PMC article. - Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, Shiraishi N, Raje N, Kumar S, Picker DH, Jacob GS, Richardson PG, Munshi NC, Anderson KC. Hamasaki M, et al. Blood. 2005 Jun 1;105(11):4470-6. doi: 10.1182/blood-2004-09-3794. Epub 2005 Feb 10. Blood. 2005. PMID: 15705788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous